SCHEDULE: Nutriband CEO Discloses Stake, Future Investment Plans

Nutriband Inc. CEO Gareth Sheridan has updated his beneficial ownership filing, detailing his current stake and outlining potential future stock transactions.

Summary

• Gareth Sheridan, CEO of Nutriband Inc., has filed an amendment to his Schedule 13D, reporting beneficial ownership of 1,786,000 shares of common stock.
• These shares represent 14.2% of the company's outstanding common stock, based on 12,155,983 shares outstanding as of September 14, 2026.
• The reported shares include 1,510,000 founder's shares issued in 2016 and 276,000 shares underlying unexercised options.
• Sheridan has not exercised any options granted under the company's stock option plan, which has an amended and restated date of March 20, 2024.
• The filing indicates potential future actions, including purchasing additional shares or selling existing shares, depending on market conditions and company evaluation.
• Sheridan may also engage in discussions with the Board and management regarding business combinations, strategic alternatives, capital structure, governance, and strategy.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily reflecting routine disclosures of beneficial ownership and potential future investment activities rather than significant new developments.

Positives

• CEO maintains a significant ownership stake (14.2%) in Nutriband Inc., aligning management interests with shareholders.
• The filing indicates potential for future investment, suggesting confidence in the company's prospects.
• Disclosure of founder's shares and options provides transparency into the CEO's equity holdings.

Negatives

• The filing does not report any new material developments or significant positive operational updates.
• The potential to sell shares could introduce downward pressure on the stock price if executed.

Risks

• Future stock sales by the Reporting Person could negatively impact the stock price.
• The company's principal business is medical device research and development, which inherently carries significant R&D and market adoption risks.
• The CEO's future investment decisions are subject to market and other conditions, introducing uncertainty.

Future Outlook

The filing indicates that the Reporting Person may purchase additional shares or sell existing shares depending on market and other conditions. Discussions regarding potential business combinations, strategic alternatives, capital structure, governance, and strategy are also anticipated.

Management Comments

• The Reporting Person holds the common stock of the Issuer for investment purposes.
• Any actions Reporting Person might undertake will be dependent upon the Reporting Person's evaluation of numerous factors, including, among other things, the price levels of the common stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects, the relative attractiveness of alternative business and investment opportunities, investor's need for liquidity, and other future developments.
• From time to time the Reporting Persons may engage in discussions with the Board and/or members of the Issuer's management team concerning, including, without limitation, potential business combinations and strategic alternatives, the business, operations, capital structure, governance, management, strategy of the Issuer and other matters concerning the Issuer.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common for significant beneficial owners, especially insiders like CEOs, to disclose their holdings and intentions. This filing by Nutriband's CEO is typical for a company in the medical device R&D sector where insider ownership and strategic discussions are key.

Stakeholder Impact

• Shareholders: Potential for stock price fluctuations based on the CEO's future buying or selling activities. Increased transparency on insider holdings is generally positive.
• Management: Potential for strategic discussions and changes in corporate direction.
• Employees: Indirect impact through potential changes in company strategy or governance.

Next Steps

• The Reporting Person may purchase additional shares of common stock or equity securities of the Issuer.
• The Reporting Person may sell all or a portion of the shares of common stock of the Issuer now beneficially owned.
• The Reporting Person may engage in discussions with the Board and/or members of the Issuer's management team concerning business combinations, strategic alternatives, capital structure, governance, and strategy.

Key Dates

Keywords

Nutriband Inc., Schedule 13D, Beneficial Ownership, Gareth Sheridan, CEO, Founder's Stock, Stock Options, Investment